Locametz Generic Name & Formulations
Gallium Ga 68 gozetotide; per kit; containing gozetotide 25mcg/vial; lyophilized pwd for IV inj after reconstitution and radiolabeling. After radiolabeling with gallium-68, contains up to 1369MBq (37mCi) in up to 10mL.
Radioactive diagnostic agent.
Kit—1 (multiple-dose vial)
For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; or for selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.
Locametz Dosage and Administration
See full labeling. Verify the total radioactivity in the syringe with a dose calibrator immediately before and after administration. Give 111–259MBq (3–7mCi), as a slow IV inj. Starting 50–100mins after IV inj, acquire PET image. The effective radiation dose from 259MBq (7mCi) dose is 4.4mSv.
Locametz Boxed Warnings
Risk of radiation exposure. Ensure adequate hydration. Advise to void immediately prior to and frequently during the first hours after image acquisition. Should only be used by trained and experienced physicians in the safe use and handling of radionuclides to minimize radiation exposure. Risk for image misinterpretation and other errors.
Androgen deprivation therapy and other therapies targeting the androgen pathway (eg, androgen receptor antagonists) can change the uptake of gallium Ga 68 gozeotide.
Locametz Adverse Reactions
Fatigue, nausea, constipation, vomiting.
Locametz Clinical Trials
Locametz Patient Counseling